Roche Palo Alto LLC

Helsinn Healthcare Sa

Helsinn Advanced Synthesis Sa

Enrico Braglia

Roberta Cannella

Daniele Bonadeo

Thomas R Malefyt

Andrew R Miksztal

Kathleen M Lee

Giorgio Calderari

Sergio Cantoreggi

Alberto Macciocchi

Riccardo Braglia

Waldo Mossi

Patrizio Aspari

Ricardo Braglia

Luigi Baroni

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Liquid pharmaceutical formulations of palonosetron

A process for the preparation of 13-cis-retinoic acid (I) from 3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienyl)-triphenylphosphonium chloride (IIa) and 5-hydroxy-4-methyl-2(5H)-furanone (III) is herein disclosed. Compounds (IIa) and (III) are reacted in ethanol as the solvent and KOH as the base at a temperature ranging from &#x2212;5 to 0&#xb0; C. to give a mixture of retinoic acids which is isomerized to (I) by treatment with a palladium complex.

Process for the preparation of 13-cis-retinoic acid

Growing community of inventors

Pazzallo, Switzerland

Enrico Braglia